NEUP (Neuphoria Therapeutics) Debt-to-Asset : 0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NEUP Neuphoria Therapeutics Inc NEUP
26 GF Score
Price $3.71
! 1 Warning Sign
View Full Analysis

What is Neuphoria Therapeutics Debt-to-Asset?

Neuphoria Therapeutics NEUP 26 Debt-to-Asset is 0.00 as of Jun. 2026. GuruFocus rates NEUP with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Neuphoria Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.03 Mil. Neuphoria Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.00 Mil. Neuphoria Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $28.71 Mil. Neuphoria Therapeutics's debt to asset for the quarter that ended in Jun. 2026 was 0.00.

Neuphoria Therapeutics  (NAS:NEUP) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Neuphoria Therapeutics Debt-to-Asset Related Terms

Neuphoria Therapeutics Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Neuphoria Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuphoria Therapeutics Debt-to-Asset Chart

Neuphoria Therapeutics Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.00

Neuphoria Therapeutics Quarterly Data
Mar24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial 0.01 0.00 0.00 0.00 0.00

NEUP vs COCP, AKTX, LGVN: Debt-to-Asset Comparison

For the Biotechnology subindustry, Neuphoria Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuphoria Therapeutics Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuphoria Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Neuphoria Therapeutics's Debt-to-Asset falls into.


NEUP
26GF Score
Neuphoria Therapeutics Inc NEUP
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuphoria Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Neuphoria Therapeutics's Debt-to-Asset for the fiscal year that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.034345000000162 + 0) / 28.709016000135
=0.00

Neuphoria Therapeutics's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.034345000000162 + 0) / 28.709016000135
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.00 mean?
Neuphoria Therapeutics (NEUP) has a Debt-to-Asset of 0.00 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Neuphoria Therapeutics and its competitors.
Is Neuphoria Therapeutics' Debt-to-Asset too high?
Neuphoria Therapeutics' current Debt-to-Asset is 0.00. Overall, Neuphoria Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Neuphoria Therapeutics' Debt-to-Asset compare to COCP and AKTX?
Neuphoria Therapeutics' Debt-to-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Neuphoria Therapeutics and its competitors. Neuphoria Therapeutics's current Debt-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuphoria Therapeutics stock overvalued right now?
Neuphoria Therapeutics (NEUP) has a current Debt-to-Asset of 0.00. The current Debt-to-Asset is 0.00. Neuphoria Therapeutics' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Neuphoria Therapeutics (NEUP), the current Debt-to-Asset is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neuphoria Therapeutics Business Description

Address 100 Summit Drive, Burlington, MA, USA, 01803
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
26GF Score

Get the complete analysis for NEUP

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.71
Price